Vectibix Fails in Treating Metastatic Colon Cancer
Those randomized to panitumumab plus oxaliplatin and bevacizumab (Avastin) had a mean progression-free survival of 9.5 months compared with 11 months in the oxaliplatin/bevacizumab arm.
Panitumumab, a fully human monoclonal antibody that targets EGFr, is approved for monotherapy for chemotherapy-refractory metastatic colon cancer.
There are several tests for colon cancer that enable your doctor to find and diagnose colon cancer before it spreads, including colonoscopy.